Published research on Atorvastatin
5 peer-reviewed publications on Atorvastatin in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
In a single-arm phase II study of 36 glioblastoma patients receiving atorvastatin with standard radiotherapy and temozolomide, the 6-month progression-free survival rate was 66% with a median PFS of 7.6 months; atorvastatin was not shown to improve PFS-6, and high baseline LDL was associated with worse survival.
- Clinical trial
In paired tumor samples from the same phase II window-of-opportunity trial, two weeks of high-dose atorvastatin before surgery decreased nuclear cyclin D1 intensity and increased p27 protein expression, while ER, PR and HER2 expression did not change significantly.
- Clinical trial
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
In 50 patients with primary invasive breast cancer given high-dose atorvastatin for two weeks before surgery, HMGCR expression was up-regulated in 68% of evaluable paired tumor samples; Ki67 did not decrease significantly in the whole group but decreased by 24% in tumors expressing HMGCR before treatment.
- Observational
In a cohort of 9,135 HCV-infected veterans, statin use was associated with a 44% reduction in incident cirrhosis and a 49% reduction in incident hepatocellular carcinoma in a dose-dependent manner, with atorvastatin and fluvastatin showing the largest effects among statins.
- Observational
In a Taiwanese cohort of newly diagnosed type 2 diabetes patients, statin use was associated with lower odds of hepatocellular carcinoma (OR 0.37), with atorvastatin specifically at OR 0.31 and metformin plus atorvastatin at OR 0.30.
Atorvastatin in the catalog (specifications, pack sizes, Certificate of Analysis)